Whether you’re newly diagnosed or wanting to explore new treatments, SRF Carebox Connect provides the resources you need to find trials that could be the right fit for you. SRF...
Read More
Last week, the CONQUEST team headed to Argentina to connect with local physicians! CONQUEST is a global platform clinical trial created by the Scleroderma Research Foundation to accelerate the development...
Read More
Scleroderma research starts with you. Learn more to find out if enrolling in the CONQUER registry is right for you! In 2018, the SRF launched the CONQUER Registry—a first-of-its-kind nationwide...
Read More
Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains...
Read More
Rare Disease Day is coming soon—a time to shine a light on the millions of people living with rare diseases, like scleroderma. At the Scleroderma Research Foundation (SRF), we believe...
Read More
CONQUEST is proud to be a sponsor of the EUSTAR Course 2025, which took place from February 6-8 in Bordeaux, France. Dr. Gregory Gordon, Chief Medical Officer of the Scleroderma...
Read More
Turning hope into action begins with a strategic approach to funding scleroderma research. When it comes to our core research portfolio, our Scientific Advisory Board, made up of some of...
Read More
Navigating clinical trials can feel overwhelming, but finding accurate, reliable information shouldn’t be. Our new clinical trial page is designed to empower you with resources and support to make informed...
Read More
Today, our hearts are heavy as we join the rest of the country in witnessing the devastating fires sweeping across Los Angeles. Amid this tragedy, we hold two extraordinary people...
Read More
"Our research would not be possible without the generous support of donors." – Ruslan Medzhitov, PhD, SRF-Funded Researcher Dr. Medzhitov, Yale School of Medicine & Howard Hughes Medical Institute,...
Read More
